China National Accord Medicines Corp Ltd
China National Accord Medicines Corp Ltd operates in the health care sector, generating revenue through pharmaceutical activities, though specific product lines are not detailed in the available data.
Business. China National Accord Medicines Corp Ltd operates in the health care sector, generating revenue through pharmaceutical activities, though specific product lines are not detailed in the available data.
Analyst recommendations
5 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
China National Accord Medicines Corp Ltd operates in the health care sector, generating revenue through pharmaceutical activities, though specific product lines are not detailed in the available data.
The company maintains a conservative capital structure with a debt-to-equity ratio of 0.24 and a current ratio of 1.54, indicating adequate short-term liquidity. Total equity stands at 18.6 billion CNY against total liabilities of 30.5 billion CNY, while long-term debt is 4.5 billion CNY. Despite positive operating cash flow of 1.6 billion CNY and free cash flow of 1.8 billion CNY, the risk assessment flags medium liquidity risk and notes that net cash is negative after subtracting total debt.
Profitability metrics are modest, with a return on equity of 3.13% and return on assets of 1.18%. The company generated net income of 1.1 billion CNY on revenue of 73.4 billion CNY, resulting in a net margin of approximately 1.55%. The price-to-earnings ratio is 18.52, while the price-to-book ratio is 0.58, suggesting the market values the company below its book value. The EV/EBITDA multiple is 32.66, which is relatively high compared to the low EV/Revenue of 0.21.
Segment and geographic revenue breakdowns are not provided in the available data, preventing analysis of revenue concentration or regional exposure. The company’s activity is broadly classified under Health Care Providers & Services, but specific operational segments are not disclosed.
Historical revenue and net income trends are not available in the input data, limiting the ability to assess growth trajectory or earnings stability over time. The latest financial snapshot shows a single period of performance without comparative historical context.
Risk factors include medium liquidity risk and low dilution risk, with a key flag noting negative net cash after debt subtraction. The company’s shares outstanding are equal for basic and diluted counts at 533.7 million, indicating no significant dilutive securities currently impacting the share count.
Recent analyst observations indicate a mean price target of 26.86 CNY and a median target of 26.07 CNY, with a mean recommendation of 2.60 (leaning towards buy). There are two strong-buy ratings and one buy rating, with no hold ratings, suggesting positive analyst sentiment despite the low classification confidence.
- The company trades at a discount to book value (P/B 0.58) but carries a high EV/EBITDA multiple (32.66), reflecting low earnings relative to enterprise value.
- Liquidity is rated as medium risk due to negative net cash after debt, despite a healthy current ratio of 1.54.
- Profitability is thin, with ROE at 3.13% and net margins around 1.55%, indicating operational efficiency challenges.
- Analyst sentiment is positive, with a mean price target of 26.86 CNY implying upside from the current market price of 20.18 CNY.
- Dilution risk is low, with no difference between basic and diluted shares outstanding.
Bull / Bear case
Generated · model-assistedNet income surged 76.8% year-over-year to CNY 1.14 billion, signaling a strong recovery in profitability.
Operating income jumped 164.6% to CNY 1.51 billion, demonstrating significant improvement in core operational efficiency.
Free cash flow doubled by 100.0% to CNY 1.78 billion, enhancing liquidity and financial flexibility.
Analysts project 11.3% upside to a mean price target of CNY 26.87, indicating positive market sentiment.
Cash conversion ratio of 2.82 ranks in the top quartile, reflecting superior cash generation relative to peers.
Net margin of 0.79% falls in the bottom quartile, indicating significantly weaker profitability compared to industry peers.
Operating margin of 0.64% is in the bottom quartile, highlighting persistent challenges in controlling operational costs.
The company faces high credit risk, posing a significant threat to asset quality and potential future losses.
Revenue declined 1.3% year-over-year to CNY 73.4 billion, suggesting stagnation in top-line growth momentum.
Return on equity of 3.13% is below the cohort median, indicating inefficient use of shareholder capital.
In focus — financials by report
Revenue ¥73.42B, −1,3% YoY; Operating income +164,6% YoY.
- ▍Revenue ¥73.42B, −1,3% YoY
- ▍Operating income +164,6% YoY
- ▍Net income +76,8% YoY
- ▍Free cash flow +100,0% YoY
- ▍Net margin 1.5%
Revenue ¥74.38B, −1,5% YoY; Operating income −76,8% YoY.
- ▍Revenue ¥74.38B, −1,5% YoY
- ▍Operating income −76,8% YoY
- ▍Net income −59,8% YoY
- ▍Free cash flow −64,3% YoY
- ▍Net margin 0.9%
Revenue ¥75.48B, +2,8% YoY; Operating income +6,9% YoY.
- ▍Revenue ¥75.48B, +2,8% YoY
- ▍Operating income +6,9% YoY
- ▍Net income +7,6% YoY
- ▍Free cash flow +14,7% YoY
- ▍Net margin 2.1%
Revenue ¥73.44B, +7,4% YoY; Operating income +18,1% YoY.
- ▍Revenue ¥73.44B, +7,4% YoY
- ▍Operating income +18,1% YoY
- ▍Net income +11,2% YoY
- ▍Free cash flow +20,4% YoY
- ▍Net margin 2.0%
Revenue ¥68.36B; Operating income ¥1.95B.
- ▍Revenue ¥68.36B
- ▍Operating income ¥1.95B
- ▍Net margin 2.0%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 2,15 |
| Revenue | —no estimate | —no estimate | 76,9B CNY |
| Operating income | —no estimate | —no estimate | 1,6B CNY |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Ev To Revenueenterprise_value / revenue
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Return On Assetsnet_income / total_assets
- Cash Conversion Ratiooperating_cash_flow / net_income
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- China National Accord Medicines Corp Ltd Market data — financials · 2026-07-09
- China National Accord Medicines Corp Ltd Market data — analyst estimates · 2026-07-09
- China National Accord Medicines Corp Ltd Market data — ESG · 2026-07-09